Guidelines on erectile dysfunction.

Risk of erectile dysfunction induced by arsenic exposure through well water consumption in Taiwan. Environ Health Perspect (2008) 0.82

Psychological and interpersonal dimensions of sexual function and dysfunction. Arab J Urol (2013) 0.78

The GAy MEn Sex StudieS: erectile dysfunction among Belgian gay men. Int J Gen Med (2013) 0.76

Sildenafil can induce the onset of a cluster headache bout. Can Urol Assoc J (2014) 0.75

Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia? World J Nephrol (2015) 0.75

Aberrant Insula-Centered Functional Connectivity in Psychogenic Erectile Dysfunction Patients: A Resting-State fMRI Study. Front Hum Neurosci (2017) 0.75

Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 6.54

EAU guidelines on prostate cancer. Eur Urol (2007) 6.30

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol (2013) 4.89

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2013) 4.65

EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol (2013) 4.58

Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol (2009) 4.58

A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37

2007 Guideline for the management of ureteral calculi. Eur Urol (2007) 3.98

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol (2010) 3.95

Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93

EAU guidelines on penile cancer: 2014 update. Eur Urol (2014) 3.86

Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol (2008) 3.64

Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol (2010) 3.55

Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol (2012) 3.53

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol (2009) 3.31

Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26

Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol (2009) 3.18

A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol (2011) 3.18

Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol (2012) 3.17

Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14

Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol (2011) 3.07

The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06

Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol (2011) 3.03

Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97

European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol (2013) 2.93

Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J (2006) 2.91

Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol (2010) 2.82

Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol (2012) 2.77

Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology (2011) 2.76

Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76

Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74

Effect of sildenafil on middle-aged sexually active males with no erectile complaints: a randomized placebo-controlled double-blind study. Eur Urol (2008) 2.74

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol (2011) 2.74

A plea for integrating laparoscopy and robotic surgery in everyday urology: the rules of the game. Eur Urol (2007) 2.68

Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol (2008) 2.65

Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63

Low-intensity extracorporeal shock wave therapy--a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med (2011) 2.63

Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol (2011) 2.62

Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55

Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series. Int J Radiat Oncol Biol Phys (2011) 2.55

Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55

Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol (2013) 2.48

A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol (2009) 2.47

Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol (2012) 2.46

Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol (2012) 2.45

Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43

Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41

European Association of Urology guidelines on priapism. Eur Urol (2013) 2.41

EAU guidelines on penile curvature. Eur Urol (2012) 2.40

Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol (2010) 2.38

Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol (2007) 2.33

Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30

The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29

Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol (2011) 2.29

Laparoendoscopic single-site and natural orifice transluminal endoscopic surgery in urology: a critical analysis of the literature. Eur Urol (2010) 2.28

BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol (2005) 2.26

Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial. Eur Urol (2007) 2.24

Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. Eur Urol (2011) 2.20

Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. Urology (2011) 2.20

Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20

Bulbar urethroplasty using buccal mucosa grafts placed on the ventral, dorsal or lateral surface of the urethra: are results affected by the surgical technique? J Urol (2005) 2.19

Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. Eur Urol (2012) 2.18

Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17

Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol (2007) 2.16

Oncologic results of laparoscopic renal cryoablation for clinical T1a tumors: 8 years of experience in a single institution. Urology (2010) 2.15

A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol (2010) 2.13

Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry (2006) 2.13

Guidelines on Testicular Cancer: 2015 Update. Eur Urol (2015) 2.11

Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU Int (2012) 2.10

Peyronie's disease and autoimmunity—a real-life clinical study and comprehensive review. J Sex Med (2015) 2.08

Pelvic lymph node dissection for prostate cancer: adherence and accuracy of the recent guidelines. Int J Urol (2012) 2.08

Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. Int J Urol (2012) 2.08

Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol (2014) 2.08

High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol (2011) 2.06

Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection. J Urol (2010) 2.05

EAU guidelines on surgical treatment of urinary incontinence. Eur Urol (2012) 2.05

Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer? J Clin Oncol (2014) 2.05

Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. BJU Int (2012) 2.03

High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol (2007) 2.02

Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol (2006) 2.02

11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol (2008) 2.00

Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol (2010) 1.99

Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. BJU Int (2011) 1.99

The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int (2013) 1.99

Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol (2008) 1.98

EAU guidelines on chronic pelvic pain. Eur Urol (2009) 1.97

Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. Eur Urol (2006) 1.96

EAU guidelines on testicular cancer: 2011 update. Eur Urol (2011) 1.96

Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: a randomised controlled study. Eur Urol (2010) 1.95

Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses. Eur Urol (2012) 1.93